Cargando…

The role of erlotinib and the Optune device in a patient with an epidermal growth factor receptor viii amplified glioblastoma

The standard treatment for patients diagnosed with glioblastoma is surgical resection of tumor followed by high dose radiation and chemotherapy with temozolomide. For patients who experience allergic reactions to temozolomide despite desensitization protocols, alternative therapies must be considere...

Descripción completa

Detalles Bibliográficos
Autores principales:	Doyle, Sean P, Gurbani, Saumya S, Ross, Alexandra S, Rosen, Havi, Barrett, Charlice Dunn, Olson, Jeffrey J, Shim, Hyunsuk, Shu, Hui-Kuo, Sengupta, Soma
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2018
Materias:	Case Report
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6217712/ https://www.ncbi.nlm.nih.gov/pubmed/30410775 http://dx.doi.org/10.1093/omcr/omy095

Ejemplares similares

Presentation of treatment effect in glioblastoma after dose-escalation radiation therapy
por: Cicka, Danielle, et al.
Publicado: (2019)

Tumor Treating Fields for Glioblastoma Treatment: Patient Satisfaction and Compliance With the Second-Generation Optune(®) System
por: Kinzel, Adrian, et al.
Publicado: (2019)

Remarkable response of a patient with secondary glioblastoma to a histone deacetylase inhibitor
por: Gurbani, Saumya S, et al.
Publicado: (2020)

Final Report on Clinical Outcomes and Tumor Recurrence Patterns of a Pilot Study Assessing Efficacy of Belinostat (PXD-101) with Chemoradiation for Newly Diagnosed Glioblastoma
por: Xu, Karen, et al.
Publicado: (2022)

NQPC-9 CHARACTERIZATION AND MANAGEMENT OF DERMATOLOGIC ADVERSE EVENTS WITH OPTUNE® IN WAKAYAMA MEDICAL UNIVERSITY HOSPITAL
por: Fukai, Junya, et al.
Publicado: (2022)

Stability of Programmable Shunt Valve Settings with Simultaneous Use of the Optune Transducer Array: A Case Report
por: Chan, Andrew K, et al.
Publicado: (2016)

The Longitudinal Imaging Tracker (BrICS-LIT):A Cloud Platform for Monitoring Treatment Response in Glioblastoma Patients
por: Ramesh, Karthik, et al.
Publicado: (2020)

Assessing Treatment Response of Glioblastoma to an HDAC Inhibitor Using Whole-Brain Spectroscopic MRI
por: Gurbani, Saumya S., et al.
Publicado: (2019)

Simulating the Effect of Spectroscopic MRI as a Metric for Radiation Therapy Planning in Patients with Glioblastoma
por: Cordova, J. Scott, et al.
Publicado: (2016)

A multi-institutional pilot clinical trial of spectroscopic MRI-guided radiation dose escalation for newly diagnosed glioblastoma
por: Ramesh, Karthik, et al.
Publicado: (2022)

Continuous inhibition of epidermal growth factor receptor phosphorylation by erlotinib enhances antitumor activity of chemotherapy in erlotinib-resistant tumor xenografts
por: IWAI, TOSHIKI, et al.
Publicado: (2011)

The Brain Imaging Collaboration Suite (BrICS): A Cloud Platform for Integrating Whole-Brain Spectroscopic MRI into the Radiation Therapy Planning Workflow
por: Gurbani, Saumya, et al.
Publicado: (2019)

Mutant Isocitrate Dehydrogenase 1 Expression Enhances Response of Gliomas to the Histone Deacetylase Inhibitor Belinostat
por: Chang, Chi-Ming, et al.
Publicado: (2023)

A Systematic Pipeline for the Objective Comparison of Whole-Brain Spectroscopic MRI with Histology in Biopsy Specimens from Grade 3 Glioma
por: Cordova, J. Scott, et al.
Publicado: (2016)

RELAY, Ramucirumab Plus Erlotinib Versus Placebo Plus Erlotinib in Patients with Untreated, Epidermal Growth Factor Receptor Mutation-Positive, Metastatic Non-Small-Cell Lung Cancer: Safety Profile and Manageability
por: Nadal, Ernest, et al.
Publicado: (2021)

Epidermal Growth Factor Receptor Inhibition with Erlotinib Partially Prevents Cisplatin-Induced Nephrotoxicity in Rats
por: Wada, Yukihiro, et al.
Publicado: (2014)

Luteolin enhances erlotinib’s cell proliferation inhibitory and apoptotic effects in glioblastoma cell lines
por: Powe, Erika, et al.
Publicado: (2022)

A Novel Approach to Determining Tumor Progression Using a Three-Site Pilot Clinical Trial of Spectroscopic MRI-Guided Radiation Dose Escalation in Glioblastoma
por: Ramesh, Karthik K., et al.
Publicado: (2023)

Factor VIII companion diagnostic for haemophilia
por: Hu, Chunxiao, et al.
Publicado: (2022)

A Novel Insertion Mutation on Exon 20 of Epidermal Growth Factor Receptor, Conferring Resistance to Erlotinib
por: Khan, Nawazish A., et al.
Publicado: (2014)

Epidermal growth factor receptor in glioblastoma
por: Xu, Hongsheng, et al.
Publicado: (2017)

Inflammatory Role of Milk Fat Globule–Epidermal Growth Factor VIII in Age‐Associated Arterial Remodeling
por: Ni, Leng, et al.
Publicado: (2022)

The Published Scientific Literature on COVID-19: An Analysis of PubMed Abstracts
por: Kang, Mohleen, et al.
Publicado: (2020)

A Phase 3b Study for Management of Ocular Side Effects in Patients with Epidermal Growth Factor Receptor-Amplified Glioblastoma Receiving Depatuxizumab Mafodotin
por: Vize, Colin J., et al.
Publicado: (2023)

Erlotinib in wild type epidermal growth factor receptor non-small cell lung cancer: A systematic review
por: Jazieh, Abdul-Rahman, et al.
Publicado: (2013)

Regulation of Epidermal Growth Factor Receptor Signaling and Erlotinib Sensitivity in Head and Neck Cancer Cells by miR-7
por: Kalinowski, Felicity C., et al.
Publicado: (2012)

Erlotinib eradicates brain metastases from epidermal growth factor receptor mutant non-small cell lung cancer
por: Jabbari, Siavash, et al.
Publicado: (2011)

Effect of the molecular targeted drug, erlotinib, against endometrial cancer expressing high levels of epidermal growth factor receptor
por: Nishimura, Toshio, et al.
Publicado: (2015)

Erlotinib is effective in pancreatic cancer with epidermal growth factor receptor mutations: a randomized, open-label, prospective trial
por: Wang, Jack P., et al.
Publicado: (2015)

Synchronous Duodenal Cancer and Lung Cancer Harboring an Epidermal Growth Factor Receptor Mutation Treated with Erlotinib and Oral Fluoropyrimidine
por: Akiyama, Norimichi, et al.
Publicado: (2017)

Targeting Epidermal Growth Factor Receptor by MiRNA-145 Inhibits Cell Growth and Sensitizes NSCLC Cells to Erlotinib
por: Amri, Jamal, et al.
Publicado: (2019)

Cogne VIII
por: CERN. Geneva. SPS-LEAR Experiments Committee
Publicado: (1995)

Enrique VIII
por: Bowle, John
Publicado: (1970)

Enrique VIII
por: Erlanger, Philippe, 1903-1987

Hæmatology—VIII
Publicado: (1910)

Successful erlotinib rechallenge after both gefitinib- and erlotinib-induced interstitial lung diseases
por: Arakawa, Nobuhito, et al.
Publicado: (2013)

Combination Erlotinib-Cisplatin and Atg3-Mediated Autophagy in Erlotinib Resistant Lung Cancer
por: Lee, Jasmine G., et al.
Publicado: (2012)

Effects of erlotinib therapy on [(11)C]erlotinib uptake in EGFR mutated, advanced NSCLC
por: Bahce, Idris, et al.
Publicado: (2016)

Impact of cellular folate status and epidermal growth factor receptor expression on BCRP/ABCG2-mediated resistance to gefitinib and erlotinib
por: Lemos, C, et al.
Publicado: (2009)

Intercalated chemotherapy and erlotinib for non-small cell lung cancer (NSCLC) with activating epidermal growth factor receptor (EGFR) mutations
por: Zwitter, Matjaz, et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_pd2m0ppspj1icatcurinsb77dc